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Mitofusin/Mfn1/Mfn2/Fzo1
OPA1/Mgm1Mitochondrial fusion is a fundamental process driven by dynamin related GTPase proteins (DRPs), in contrast
to the general SNARE-dependence of most cellular fusion events. The DRPs Mfn1/Mfn2/Fzo1 and OPA1/
Mgm1 are the key effectors for fusion of the mitochondrial outer and inner membranes, respectively. In
order to promote fusion, these two DRPs require post-translational modiﬁcations and proteolysis. OPA1/
Mgm1 undergoes partial proteolytic processing, which results in a combination between short and long
isoforms. In turn, ubiquitylation of mitofusins, after oligomerization and GTP hydrolysis, promotes and pos-
itively regulates mitochondrial fusion. In contrast, under conditions of mitochondrial dysfunction, negative
regulation by proteolysis on these DRPs results in mitochondrial fragmentation. This occurs by complete
processing of OPA1 and via ubiquitylation and degradation of mitofusins. Mitochondrial fragmentation con-
tributes to the elimination of damaged mitochondria by mitophagy, and may play a protective role against
Parkinson's disease. Moreover, a link of Mfn2 to Alzheimer's disease is emerging and mutations in Mfn2 or
OPA1 cause Charcot–Marie–Tooth type 2A neuropathy or autosomal-dominant optic atrophy. Here, we
summarize our current understanding on the molecular mechanisms promoting or inhibiting fusion of mito-
chondrial membranes, which is essential for cellular survival and disease control. This article is part of a
Special Issue entitled: Mitochondrial dynamics and physiology.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Mitochondria are very dynamic organelles, whose morphological
changes are achieved by constantly occurring fusion and ﬁssion
events [1]. Loss of mitochondrial fusion is characterized by the
presence of fragmented mitochondria, produced by ongoing ﬁssion,
which contrasts to the characteristic network of most cellular types.
Mitochondrial ﬁssion not only allows proper distribution of mito-
chondria, for example to cope with local ATP demands, but also
contributes to selective removal of damaged organelles. Fusion of mi-
tochondrial membranes, in turn, allows organelle content mixing and
prevents mitochondrial DNA loss, facilitating maximal ATP produc-
tion. Mitochondrial fusion is particularly important in the nervous
system, helping neurons to meet the high energy demands for proper
neuronal function, by diluting out injury and dysfunction to which
each individual mitochondrion is subject [2,3]. Mitochondrial fusion
therefore plays a protective role, preventing these deﬁciencies from
damaging the entire neuron while maintaining an adequate level of
bioenergetic capacity [4,5].drial dynamics and physiology.
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tion as a contributor to both common and rare neurodegenerative
diseases. Early discoveries showed the direct role of the central fusion
components in the autosomal-dominant optic atrophy (ADOA) and in
the Charcot–Marie–Tooth type 2A neuropathy (CMT2A) [6–9]. More
recently, a link between mitochondrial fusion and the most common
neurodegenerative diseases of the aging population, and also a link
with cardiopathies, were observed [10–12]. Interestingly, the
ubiquitylation of mitofusins by the Parkin E3 ligase (often mutated
in Parkinson's disease patients) appears to contribute in targeting
damaged mitochondria for degradation, which could protect against
Parkinson's disease [13–15]. Because these topics are detailed in ac-
companying reviews in this issue, here we focus on the molecular
mechanisms that either prevent or promote mitochondrial fusion.
This leads to the opposite outcomes of mitochondrial tubulation or
fragmentation. In this respect, it is interesting to notice that mito-
chondrial fusion recently joined a group of fundamental processes,
such as transcription or cellular trafﬁcking, which are controlled by
ubiquitylation.
Mitochondrial fusion occurs if two tips or one tip and one tubule
come together. The ﬁeld emerged essentially with pioneer observa-
tions of fusion events and with the identiﬁcation of the ﬁrst protein re-
quired for fusion, Fzo, in ﬂy [16–18]. Studies initially based on genetic
screens, coupled with observations of mitochondrial morphology,
allowed the identiﬁcation of most proteins involved in mitochondrial
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physical interactions between the different proteins have allowed the
ﬁeld to progress. In addition, the development of cell free in vitro
tethering and fusion assays was of outmost importance [21–25]. Inter-
estingly, the discovery of the yeast and mammalian homologs of Fzo
[18,26–28] was an early indicator for common mechanisms and
indeed the basic principles in mitochondrial fusion have proven to be
conserved.
2. The key mediators of mitochondrial fusion
While the vast majority of the membrane fusion events in a cell
are performed by SNAREs, fusion of mitochondria and of the
endoplasmic reticulum (ER) depends on dynamin-related proteins
(DRPs) [29–32]. DRPs are a special class of GTPases, which provide
the mechanical forces necessary for membrane remodeling [33,34].
They are best known for their role in membrane scission events, par-
ticularly during endocytosis and certain other membrane budding
events, and also perform ﬁssion in mitochondria and peroxisomes
[35,36]. The key DRPs involved in mitochondrial fusion are conserved
in yeast, worms, ﬂies, mice and humans (Table 1).
2.1. Mitofusins, the DRPs in the OM
Mitofusins, the DRPs that mediate fusion of mitochondrial outer
membranes (OM), are termed Mfn1 and Mfn2 in mammals, Fzo and
Marf/Dmfn in ﬂies, FZO-1 in the worm and Fzo1 in budding yeast.
In contrast to the founding member identiﬁed, FZO, shortly expressed
during ﬂy spermatid development [18], all the other mitofusins are
constitutively expressed ubiquitous mitochondrial proteins, in both
males and females [26,28,37–40]. Loss of Fzo1 in yeast leads to loss
of mitochondrial DNA and consequently loss of mitochondrial trans-
lation, resulting in respiratory incompetence [26,27]. In ﬂies Fzo loss
leads to male sterility [18], and in mice Mfn1 KO or Mfn2 KO is
embryonic lethal due to a placental defect [4]. Moreover, if Mfn2 is
depleted only after placental formation, mice show impaired cerebel-
la development and lethality at day 1 post-birth [5]. In contrast, mice
are normal if depleted of Mfn1 only after placental formation [5],
suggesting that after this stage Mfn1, but not Mfn2, is dispensable.
Isolated cells lacking both Mfn1 and 2 showed severe cellular defects,
including poor cell growth, widespread heterogeneity of mitochon-
drial membrane potential and decreased cellular respiration, whereas
single Mfn KO escaped major cellular dysfunction [41]. In addition,
Mfn2 depletion leads to a loss or reduction of membrane potential
[4,42].
Mitofusins are localized throughout the mitochondrial network
[26,28,37,39,40]. They are anchored to the OM by two transmem-
brane domains, and their N-terminus and C-terminus are exposed
to the cytoplasm [18,26,27,37,43] (see Table 1 and Fig. 1). The N-
terminus comprises the GTPase domain, followed by one coiled-coil
heptad repeat (HR1). Moreover, yeast, worm and ﬂy mitofusins
have one additional coiled-coil motif upstream of the GTPase domain
(HRN) (see Table 1). Although no equivalent coiled-coil is present in
mammalian mitofusins, the N-terminal region upstream of the
GTPase domain in Mfn2 is also essential for its function [44]. In
turn, the C-terminal domain of mitofusins possesses one additional
coiled-coil heptad repeat (HR2). All HR domains are required for
mitofusin function, at least in yeast [45]. Importantly, mutations in
the conserved GTPase P-loop or switch motifs abolished mitochondri-
al fusion in all organisms, indicating that both GTP binding and
hydrolysis are conserved requirements [4,18,26,45–47].
As expected for DRPs, mitofusins self-assemble [27,39] and in
mammals as in yeast, GTP induced changes in the three oligomeriza-
tion states detected [47,48]. P-loop mutants were exclusively present
in a lower molecular weight form, being the wild-type Fzo1 or Mfn1
recovered in a complex with a middle molecular weight [47,48].After trans associations, i.e. associations between two mitochondria,
the middle molecular weight complex then shifted to the higher olig-
omerization state [47,48]. Recent studies in yeast clearly demonstrat-
ed that the smaller complex corresponds to the monomeric form of
the protein, whereas the middle complex represents a dimer in cis
(in the same mitochondria), formed upon GTP binding [47]. The olig-
omeric state of the bigger trans complex has not been clearly deﬁned,
but was compatible with the formation of a tetramer in trans [47].
In addition to the oligomerization of full-length mitofusins, their
N-terminal HR1 and C-terminal HR2 interact with each other
[37,45]. This interaction is GTPase dependent, because it is not formed
in GTP binding or hydrolysis mutants [44,45], and also depends on an
intact N-terminal domain [44]. Moreover, co-expression of non-
overlapping halves of Fzo1 domains partially complements the
wild-type protein, showing that different domains can be provided
in separate molecules [45].
2.2. OPA1/Mgm1, the DRP promoting fusion in the IM
The key mediator of inner mitochondrial membrane fusion is
called Mgm1 in budding yeast, Msp1 in ﬁssion yeast, eat-3 in the
worm and OPA1 in ﬂies and mammals [6,7,49–59]. OPA1 is expressed
in all tissues analyzed and both in vivo and in isolated mitochondria
Mgm1/OPA1 is localized to discrete foci in interface regions of the
IM [22,53,60,61]. Loss of Mgm1 leads to respiratory incompetence in
yeast due to mitochondrial DNA loss and OPA1 KO in mice is embry-
onic lethal [49,62,63]. In addition, OPA1 repression in mammals de-
creases cell growth and oxygen consumption [41,64–67]. Mutations
in OPA1 cause ADOA, characterized by progressive bilateral blindness
due to the loss of retinal ganglion cells and optic nerve deterioration
[6,7,68]. Consistently, heterozygous mutant OPA1 mice show a visual
impairment resembling the human ADOA [62,63]. OPA1 mutations
are associated with multiple deletions in mitochondrial DNA and
also with other neurological conditions adding to ADOA, called
“OPA1 plus” phenotype. This consists of chronic progressive
ophthalmoplegia, ataxia, sensironeuronal deafness, sensory‐motor
neuropathy and myopathy [68]. Moreover, in addition to its funda-
mental role in mitochondrial fusion, OPA1/Mgm1 is also required
for cristae formation [22,65,69–72]. Loss of OPA1/Msp1 leads to cell
death [64,65,73] and increases sensitivity to apoptosis, which was
proposed to occur via increased release of cytochrome c due to
widened cristae junctions [65,66,67,70,72,74–76]. The structural role
of OPA1/Mgm1 in cristae formation occurs via oligomeric self-
interactions and was suggested to be independent of ongoing mito-
chondrial fusion, because it was not abolished in the absence of
Mfn1 [75]. However, inactivation of the main ﬁssion machinery com-
ponent, Dnm1, reverses the cristae morphology phenotype of yeast
Mgm1 mutants [69].
OPA1/Mgm1 is present in the IM with long, membrane anchored,
and short soluble forms, both required for IM fusion [77,78]. These
short and long isoforms constitute a complex pattern regulated both
post-transcriptionally and post-translationally. In mammals, alterna-
tive splicing of the mRNA creates several long isoforms, which are
processed to yield several short isoforms [67,79,80], whereas in
yeast there is only one long and one short isoform [77,81,82]. All
OPA1 variants possess a mitochondrial targeting sequence, cleaved
upon import. This sequence is followed by a transmembrane segment
that anchors the long isoforms in the inner membrane (IM), with the
bulk of the protein facing the intermembrane space (IMS) (Table 1
and Fig. 1). The short isoforms are constitutively generated by further
proteolytic maturation at the S2 cleavage site (Table 1) [83]. Only a
fraction of the long isoforms is cleaved, thereby producing equimolar
amounts of long and short isoforms. This cleavage is performed by
Pcp1 in yeast [77,81,82] and was found to depend on cellular ATP
levels [84]. In mammals, it was shown that constitutive processing
at the S2 cleavage site depends on YME1L [78,85]. However, other
Table 1
Domain structure of mitochondrial fusion proteins. Representation of the function, domain structure and localization of the proteins involved in mitochondrial fusion, i.e.
dynamin-related proteins (DRPs) and accessory proteins (accessory). In case of mammalian proteins, the Homo sapiens homolog is represented. Dm, Drosophila melanogaster;
Ce, Caenorhabditis elegans; Sc, Saccharomyces cerevisiae. The triangle on OPA1/Mgm1 indicates cleavage sites.
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Fzo-1
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MIB
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MitoPLD
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stitutive levels of some OPA1 isoforms [86–88]. Downstream of the
S2 cleavage site, all OPA1/Mgm1 forms possess one coiled-coil do-
main, followed by the typical DRP motifs: GTPase, middle and GED
domains (Table 1), all essential to promote IM fusion [22,69,89,90].
This combination between short and long isoforms certainly contrib-
utes to IM fusion regulation, because Mgm1 cleavage into the short
isoforms results in activation of its GTPase activity, which is only re-
quired on the short isoforms [91,92]. In turn, long isoforms could be
required to target the short forms via self-interactions [22,91,92].
3. Mitochondrial fusion accessory proteins
In addition to the DRPs, mitochondrial fusion depends on several
other proteins (Fig. 1 and Table 1). Fusion of the IM requires Pcp1/
Rho-7 in yeast and ﬂies, YME1L in mammals and Ugo1 in yeast. In
turn, OM fusion is modulated by Ugo1 and Mdm30 in yeast,MitoPLD/Zuc in mammals and ﬂies, and Bax and MIB in mammals.
Despite the high conservation between mitofusins, they are not inter-
changeable between yeast, ﬂy and mammals [39], possibly due to the
lack of conservation of some of the accessory proteins discovered so
far.
3.1. Pcp1/Rho-7/PARL, IM fusion activator
Pcp1 in yeast, Rho-7 in ﬂy and PARL (presenilin-associated
rhomboid-like) in mammals are the mitochondrial rhomboid prote-
ases. They possess seven membrane-spanning regions and are local-
ized to the IM [93,94]. Rhomboid proteases comprise a conserved
protein family of integral membrane serine endoproteases, which
generally clip substrate proteins within their membrane-spanning
segment [95–97]. Pcp1 modulates mitochondrial morphology in
yeast because it processes Mgm1 [77,81,82]. Although PARL
expressed in yeast can process Mgm1 [82], its role in OPA1 processing
Ugo1
Mdm30
Mitofusin
MitoPLD
Bax
OM
l-OPA1/Mgm1
Pcp1
YME1L
MIB
IM IMS Cytoplasm
s-OPA1/Mgm1
Matrix
Fig. 1. Topology of mitochondrial fusion proteins. The topology and localization of the proteins involved in mitochondrial fusion, shown in Table 1, are depicted. The proteins are
represented in their predominant oligomeric state.
165M. Escobar-Henriques, F. Anton / Biochimica et Biophysica Acta 1833 (2013) 162–175is still controversial. Indeed, it was reported that PARL is involved in
the release of short OPA1 isoforms frommitochondria during apopto-
sis [76], but OPA1 processing occurs in the absence of PARL/Rho-7
[85,98].
3.2. YME1L, more than a quality control regulator
The i-AAA protease is one of the ATP-dependent quality control AAA
proteases responsible for the recognition and degradation of
miss-folded proteins in mitochondria [99–101]. Located in the IM, it
has its catalytic center facing the inter membrane space (Fig. 1). It is a
homohexamer composed of Yme1/YME1L subunits, which form a pro-
teolytic chamber allowing proteolysis to occur in a sequestered envi-
ronment. In mammals, YME1L is important for IM fusion because it is
responsible for cleavage of the long OPA1 isoforms at the S2 site [78,85].
3.3. Ugo1, the coordinator of OM and IM fusion
Ugo1, which means “fusion” in Japanese, is an OM protein that is
essential for fusion of yeast mitochondria both in vivo [102] and in
vitro [103]. It is a modiﬁed carrier protein [104], containing three
TM domains, which dimerizes [103]. This creates a complex with 6
TM domains, typical of carrier proteins. However, a transporter func-
tion has not yet been assigned to Ugo1. Recent studies revealed that
the Ugo1 protein interacts with the recently identiﬁed MICOS/
MITOS/MINOS complex, a large contact site scaffold-like protein com-
plex, which controls mitochondrial architecture and biogenesis[105–107]. Importantly, Δugo1 cells had a drastic reduced number
of cristae and cristae junctions [107].
Interestingly, pioneer microscopy studies reported that mitochon-
drial fusion initiates at sites of close apposition of the IM and OM
[108]. Consistently, biochemical fractionation revealed that Fzo1 lo-
calizes at contact sites of the IM with the OM [26]. This localization
depends on the small 6–10 aa loop of Fzo1 present in the IMS [43]
and is required for mitochondrial fusion [43]. Moreover, OPA1 re-
quires Mfn1 to stimulate mitochondrial fusion, supporting a con-
served interdependence of OM and IM fusion.
The Ugo1 protein was proposed to coordinate yeast OM and IM fu-
sion, which occur simultaneously in vivo [31,89], due to its physical
interactions with both Fzo1 and Mgm1 [89,109]. Ugo1 interacts
directly with Fzo1, independently of Mgm1, via its cytosolic
N-terminal domain. Furthermore, it also interacts with Mgm1, inde-
pendently of Fzo1, via its C-terminal and IMS domain [89,109]. In
vitro fusion assays revealed that indeed Ugo1 is required for fusion
of both mitochondrial membranes [103]. Ugo1 might function as an
adaptor between IM and OM DRPs [103], because the protein com-
plex between Fzo1 and Mgm1 depends on Ugo1 [109]. However,
physical interactions of Ugo1 with each DRP are not sufﬁcient to
drive mitochondrial fusion [103], as shown with UGO1 mutant strains
incapable to fuse. This suggests that the role of Ugo1 goes beyond that
of a simple adaptor. Although not conserved, a structural or function-
al ortholog of Ugo1 might exist among the many members of the
transport/carrier protein family in humans. In fact, mammalian OM
and IM DRPs also interact physically.
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largely capable to fuse with wild-type mitochondria [103]. This indi-
cates that a functional Ugo1 is only required on one mitochondrial
partner. Moreover, Ugo1 was distinctly required for either IM or OM
fusion: mutations in the IMS domains of Ugo1 blocked mitochondrial
fusion although OM fusion was not impaired. Conversely, additional
mutations in the cytoplasmic region of Ugo1 impaired OM fusion. Im-
portantly, these ugo1ts mutants have been useful for proposing a role
for Ugo1 following tethering of either mitochondrial membrane
[103]. Thus, Ugo1 could be required for mixing of the lipid mem-
branes, the last step required for membrane fusion. On the other
hand, complete absence of the Ugo1 protein impaired Fzo1 dimeriza-
tion in cis, thus affecting mitochondrial fusion before the tethering
step [47]. Therefore, Ugo1 appears to act at both early and late stages
of mitochondrial OM fusion.
3.4. Mdm30, the post-translational modiﬁer of Fzo1
Mdm30 is a cytosolic, mitochondrial-associated F-box protein that
binds and ubiquitylates Fzo1 [110–112]. The covalent binding of
ubiquitin to its substrate is catalyzed by three sequential steps,
starting with ubiquitin activation by E1 enzymes, its conjugation to
the second set of enzymes called E2, being ﬁnally transferred to its
target by the substrate-speciﬁc E3 ligases [113]. F-box proteins con-
stitute a special class of E3 ligases, called SCF complexes (Skp1,
Cdc53 and F-box), in which the F-box subunit is responsible for sub-
strate speciﬁcity [114]. In addition to Fzo1, two other substrates of the
SCFMdm30 have been described so far, Mdm34 and Gal4. Mdm34 is
one of the OM components of the ERMES complex, which promotes
physical associations between the ER and mitochondria [115–117].
Gal4 is a nuclear transcription factor responsible for the activation
of the galactose metabolism pathway [118,119]. Moreover, Mdm30
has been implicated in the stimulation of the nuclear export of certain
mRNAs [120].
Mdm30 acts at a late stage of mitochondrial OM fusion via
ubiquitylation and proteolysis of Fzo1, after trans associations and
GTP hydrolysis of Fzo1 [47,111,112,121–124]. Therefore, Mdm30
does not operate as a regulator of Fzo1 quality control but rather
acts on Fzo1 at the last step in the OM fusion process. Absence of
Mdm30 strongly impairs mitochondria fusion [110,125] and leads to
the clustering of mitochondrial fragments, as revealed by electron mi-
croscopy images [121].
3.5. MitoPLD/Zuc, the role of the lipids for OM fusion
MitoPLD belongs to the phospholipase D superfamily, being most
closely related to prokaryotic PLDs called Nuc. In contrast to the clas-
sical mammalian PLD family members, MitoPLD possesses an
HKD-half catalytic site, which by dimerization creates a functional en-
zyme [126]. It cleaves the mitochondrial-speciﬁc lipid cardiolipin to
generate PA, a signaling lipid which activates SNARE-driven fusion
events [127]. MitoPLD is anchored to the mitochondrial OM, facing
the cytoplasm, and was ﬁrst reported to promote mitochondrial OM
fusion [126]. MitoPLD downregulation or use of enzymatic inactive
variants results in mitochondrial fragmentation by inhibition of mito-
chondrial fusion. In contrast, MitoPLD overexpression leads to mito-
chondrial aggregation, dependent on the presence of mitofusins.
Similar to Mfn1 overexpression, these aggregates consist of closely
associated mitochondrial fragments. However, in each case, the spac-
ing between the fragments is different. Overexpression of Mfn1 leads
to fragments separated by 16 nm, whereas in the aggregates driven
by MitoPLD overexpression mitochondrial spacing is reduced to
6 nm [126,128]. This suggests a role for MitoPLD acting in membrane
merging following tethering by mitofusins, perhaps by hydrolysis of
cardiolipin in the opposing membrane [126]. Interestingly, cardiolipin
biosynthesis was downregulated immediately post mitochondrialfusion, rising again at later time points, suggesting a possible com-
pensatory feed-back mechanism [129]. However, whether MitoPLD
requires GTP hydrolysis by mitofusins, and which mechanism is un-
derlying the precise role of MitoPLD in mitochondrial fusion, is cur-
rently unknown [130]. Interestingly, PA generation by MitoPLD
recruits Lipin 1b, which converts PA to DAG, which in turn promotes
mitochondrial ﬁssion [131]. This supports previously reported spatio-
temporal connections between mitochondrial fusion and ﬁssion
[132,133]. In addition to its role in mitochondrial fusion, MitoPLD is
also called zucchini (Zuc) in drosophila and is required for piRNA gen-
eration, critical for germ-line development [134,135]. Zuc/MitoPLD
absence leads to a failure to suppress transposon mobilization, induc-
ing DNA-damage and check-point induced meiotic arrest, leading to
apoptosis and sterility [131,136,137].3.6. Bax, stimulation versus inhibition of mitochondrial fusion
Bax is a pro-apoptotic protein from the Bcl-2 family that regulates
mitochondrial fusion both positively and negatively. Upon apoptotic
stimuli, cytosolic Bax migrates to mitochondria, inserting itself and
oligomerizing in the OM thereby punching holes in it, allowing cyto-
chrome c to leak out and inducing apoptosis [138]. In general,
mitochondrial fusion protects against apoptosis, perhaps via mainte-
nance of cristae integrity by OPA1, avoiding cytochrome c release
[75]. Consistently, activation of apoptosis inhibits mitochondrial fu-
sion [139]. In contrast, in healthy cells, a stimulatory role of mito-
chondrial fusion from pro-apoptotic proteins like Bax and tBID has
also been reported [25,140–144]. Bax interacts with Mfn2 and in
Bax/Bak double knockout cells the focal distribution and oligomeriza-
tion of Mfn2 are impaired [140]. Consistently, Mfn2 overexpression
reversed the shorter mitochondrial tubules caused by the lack of
Bax and Bak [140,143]. In healthy cells, Bax is constantly cycling be-
tween the cytosol and the mitochondria [144]. If this cycling is
blocked, Bax loses its ability to stimulate fusion in vitro [25]. In addi-
tion, expression of a chimeric protein of Bcl-xL with helix 5 of Bax,
which shows stronger binding to Mfn2 compared to Bax, reduces
mitofusin mobility in the OM and inhibits mitochondrial fusion
[143]. Therefore, transient interactions between Bax and Mfn2 could
be required for efﬁcient fusion by modulating Mfn2 assembly or con-
centration at the fusion sites. Bax could also play a role in membrane
sculpting, due to its high propensity to insert in highly curved
membranes.
Apart from Bax, several apoptosis related proteins, Bak, Bcl-x and
Bcl-2, have been described as physical interactors of mitofusins
[145–149], suggesting a general role of Bcl-2 family proteins in the
regulation of mitochondrial morphology.3.7. MIB, a negative regulator of mitochondrial fusion
The MIB protein is important to the maintenance of tubular mito-
chondria, because its overexpression induces fragmentation and its
downregulation promotes extensive tubulation [150]. MIB appears
to be a negative regulator of mitochondrial fusion, because it physi-
cally interacts with Mfn1 and Mfn2. Consistently, MIB partially frac-
tionates with the membrane-enriched cellular extracts containing
mitochondria and ER, although it mostly localizes to the cytoplasm.
Intriguingly, if overexpressed, MIB disperses in the cytoplasm while
it induces mitochondrial fragmentation. The phenotypes of MIB de-
pend on a GGVG-conserved motif of its coenzyme-binding domain,
and are apparently independent of mitochondrial ﬁssion. It remains
to be analyzed how MIB negatively regulates mitofusin activity. In
analogy to its homolog, the VAT-1 protein, regulation could involve
the ATPase activity or Ca2+-dependent oligomeric-complex forming
activity.
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Early observations with overexpression studies suggested that in-
teractions in trans between mitofusins lead to apposed mitochondria.
Indeed, Mfn1, Mfn2 or Fzo1 overexpression leads to the formation
of spherical non-fused but closely associated mitochondrial clusters,
which display perinuclear localization in mammalian cells [28,37,
39,111]. Clustering was dependent on the C-terminal coiled coil, but
was not abolished after deletion of the GTPase motif [28,37,45]. In
addition, mutant forms of Mfn2 [40] or truncated forms of Mfn1
[128] lead to association of fragmented mitochondria. Consistently,
mitochondrial fusion both in vivo and in vitro requires mitofusins on
adjacent mitochondria [21,128]. Moreover, it appears that only one
mitofusin is required on each mitochondrion, because single KO cells
could fuse with wild-type cells, whereas no mitochondrial fusion ac-
tivity could be detected in vivo by mixing double Mfn1 Mfn2 KO
with wild-type cells [128].
Compelling evidence for trans associations of mitochondria was
provided by an in vitro docking assay, based on measurements of
the association between isolated mammalian mitochondria labeled
with different ﬂuorescent markers [48]. This assay revealed that ex-
ternal expression in wild-type cells of Mfn1, but not of Mfn2, promot-
ed mitochondrial tethering in a GTP-, temperature- and time-
dependent manner [48]. A similar assay in yeast showed that Fzo1
also promotes mitochondrial tethering, impaired in GTP binding mu-
tants [124]. Importantly, co-immunoprecipitation studies directly
demonstrated that mammalian and yeast mitofusins not only pro-
mote trans associations of mitochondria but also physically associate
in trans [47,48]. Differentially tagged mitofusins present on separate
populations of OM vesicles or on isolated mitochondria revealed the
presence of protein complexes in trans. An assay based on electron
microscopy observations allowed independent measurement of IM
[22] and OM tethering [103]. Mitochondrial tethering is identiﬁed in
regions of mitochondrial OM or IM association by the presence of
membranes tightly aligned, reciprocally deformed and evenly spaced
apart [21,103].
5. Tools to measure mitochondrial fusion
Although to date there is no direct demonstration for fusion after
reconstitution on liposomes of mitofusins and Mgm1/OPA1, there is
good in vivo and in vitro evidence that those are the proteins that
promote fusion directly. Several in vivo assays with cellular cultures,
and also in vitro assays with isolated mitochondria, are available.
They showed complete blockage of mitochondrial fusion in the ab-
sence of OPA1/Mgm1, Fzo1 and both Mfn1 and Mfn2 [21,22,25,
26,41,53,66,78,89,90,128,151] and strong impairment in the absence
of either Mfn1 or Mfn2 [4,25,40,41].
5.1. In vivo fusion assays
The ﬁrst assay reported for assessing mitochondrial fusion in vivo
was with yeast cells. It is based on mixing of mitochondria labeled
with different ﬂuorophores, during mating between two haploid cells,
and it is monitored by ﬂuorescence co-localization [17,152]. For
mammals, a similar assay is based on PEG-induced or virus-induced
whole cell fusion between two differently labeled populations of mito-
chondria [46,153]. A second assay described formammalian cells uses a
photoactivable GFP, where small populations of mitochondria are
ﬂuorescently activated and their subsequent fusion events scored
using ﬂuorescent quantiﬁcation [154]. In vivo fusion assays have dem-
onstrated that fusion is completely inhibited after depletion of Δψwith
CCCP, but can occur in rho0 cells, after ATP depletion, after depolariza-
tion of the cytoskeleton and is independent of protein synthesis
[46,153].5.2. In vitro fusion assays
Importantly, the later development of cell free assays for measur-
ing fusion events was of fundamental importance and allowed the
deﬁnition of discrete steps in mitochondrial fusion. First, an assay
using isolated yeast mitochondria labeled with various ﬂuorescent
markers allowed the assessment of content-mixing by the co-
localization of the ﬂuorophores expressed in different mitochondrial
compartments [21]. Moreover, a readily automated and quantitative
fusion assay, based on luciferase activity for assessing matrix content
mixing of isolated mammalian mitochondria, was recently developed
[24]. The critical and initial requirement for mitochondrial fusion is
that mitochondria are brought into close contact, presumably to per-
mit tethering and docking. In vitro, this is achieved by a centrifuga-
tion step followed by an incubation step on ice. Afterwards,
resuspension in the energy regeneration fusion buffer, accompanied
by temperature increase and further incubation, allowsmitochondrial
fusion [23].
In vitro fusion assays revealed that the core requirements for mito-
chondrial fusion are similar in yeast and mammalian cells [21,24,25].
First, apyrase and non-hydrolysable GTP analogs completely inhibit
mitochondrial fusion, directly demonstrating that GTP hydrolysis is
essential [21,24,25]. An intact membrane potential is essential, because
in the presence of CCCP no fusion was detected. As detailed below, this
can be explained by CCCP-induced proteolytic processing and inactiva-
tion of long OPA1 isoforms by the OMA1 protease [86,87]. Moreover,
valinomycin, and to a lower extent nigericin, also inhibited mitochon-
drial fusion, indicating that the electric more than the proton gradient
is required [21,24]. Both in yeast and in mammals, addition of cytosol
to the fusion buffer was not required for mitochondrial fusion,
conﬁrming that the core machinery is physically associated with mito-
chondria. However, in mammals, under certain conditions cytosol ad-
dition stimulated or inhibited mitochondrial fusion, suggesting the
inﬂuence of signaling pathways coming from the cytoplasm [24,25],
possibly involving phosphoproteins like PKA [24]. Interestingly, induc-
tion of apoptosis inhibited mitochondrial fusion in vitro [24], consoli-
dating previous in vivo data [154,155]. Conversely, in healthy cells,
the positive role of Bax in mitochondrial fusion [140] was also recapit-
ulated in vitro, where addition of recombinant bax stimulates Mfn2
mediated fusion [25]. This effect was also observed using an oligomer-
ization defective mutant of Bax, suggesting that the fusion promoting
role of Bax is independent of its function in apoptosis.
The ﬁrst in vitro assay of mitochondrial fusion described, although
semi-quantitative, also allows one to separately follow OM and IM fu-
sion events. Both OM and IM fusion required GTP hydrolysis and
depended on the presence of the respective DRPs in both mitochon-
dria to be fused [21,22,25]. Moreover, although impairment of
Mgm1/OPA1 completely blocked IM fusion, the competence for OM
fusion was not affected [22,25]. Interestingly, whereas IM fusion re-
quired the addition of external GTP and of an energy regeneration
system, low GTP levels were sufﬁcient to promote OM fusion. In addi-
tion, OM fusion only needed the proton gradient component (ΔpH) of
the IM electrochemical potential, perhaps to maintain membrane in-
tegrity, but not the electrical component, in turn required for IM fu-
sion. To clarify the requirements for fusion observed with isolated
mitochondria, it would be interesting to separately reconstitute
fusion events with puriﬁed OM or IM fractions.
6. Molecular mechanisms of mitochondrial fusion
As stated above, fusion of each of the two mitochondrial mem-
branes is not only performed by different machineries but also has
different energetic requirements, clearly indicating that the OM and
IM DRPs function differently [21]. The need for low GTP amounts in
OM fusion in vitro suggests that mitofusins use a different mechanism
from the classical DRPs. In contrast, IM fusion could bemore similar to
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GTP levels in the in vitro fusion assay. Nevertheless, although in clas-
sical DRPs the driving force is provided by GTP hydrolysis, the rate ob-
served for GTP hydrolysis by Mgm1 was relatively low [92,156].
Importantly, hints on how these proteins might function are provided
by the recently solved crystal structures of bacterial dynamin-like
protein (BDLP) and dynamin 1, close homologs to mitofusins and
Mgm1/OPA1, respectively [157–160]. The numerous genetic and
biochemical ﬁndings described above, together with the crystalA
GTPhydrolysis
tethering
B
Mitofusin ubiquitylation
MitoPLD, Ugo1
OM fusion
GTPbindingUgo1
GTPhydrolysis
tethering +structures of homologous DRPs, allow one to extrapolate and propose
possible mechanistic models of IM and OM fusion [32,161]. However,
it should be noted that how the different nucleotide states and trans
associations of the DRPs inﬂuence the polymer structure, and how
this is coupled to membrane fusion, are not yet clear.
6.1. OM fusion model
Early studies showed that Fzo1 and Mfn1/Mfn2 are involved in
mitochondrial docking. Physical interactions between mitofusins in
trans, allowing the alignment of mitochondrial membranes for fusion
events, have been demonstrated on both yeast and mammals [47,48].
In addition, recent work has elucidated the role of different oligomer-
ization states during mitochondrial fusion [47]. Importantly, structur-
al information from BDLP, the mitofusin homolog from cyanobacteria,
can be used to further understand mitofusin oligomers [157,158]. In
fact, the GTPase domain of mitofusins is most similar to a family of
eubacterial GTPases, suggesting that it is derived from an ancestral
prokaryote. Although the role of GTP binding and hydrolysis had
remained elusive, it is now clearer how the GTPase cycle is coupled
to individual fusion states [47]. However, direct tests of the GTPase
nucleotide bound state and activity of mitofusins in the different olig-
omerization states are still missing. After GTP hydrolysis, OM fusion
requires mitofusin ubiquitylation in yeast [47,124], which then with
the help of Ugo1, drives completion of the fusion process [103]. The
current vision of how OMs fuse, where Mfn1 structural arrangements
were modeled on BDLP, is summarized in Fig. 2.
6.1.1. Oligomerization of mitofusins—dimerization in cis and further
association in trans
As stated, several observations support both cis and trans associa-
tions between mitofusins, consistent with the intragenic interactions
observed for the classical DRPs. The crystal structure of BDLP reveals a
compact molecule in which the predicted GTPase and coiled-coil do-
mains do not form discrete entities [157]. Moreover, interactions be-
tween the GTPase domains promote BDLP dimerization [157,158],
consistent with the dimer form observed for cis complexes of yeast
mitofusin [47]. Not unexpectedly, the structure of BDLP revealed mas-
sive changes upon lipid binding, also supported by increase in the
oligomeric state of Fzo1 or Mfn1 after trans associations [47,48].
How mitofusin dimers, tetramers or possibly higher order struc-
tures assemble in trans is not yet clear. Initially, structural analysis
of the C-terminal coiled-coil of Mfn1 has revealed that it can fold
into a dimeric antiparallel helical structure that is 95A long, which
was proposed to drive mitochondrial tethering [128]. The integrity
of this coiled-coil is important, because if mutated in the full length
protein it impairs tubular morphology and mitochondrial fusionFig. 2. OM fusion model, integrating the oligomerization and GTPase properties of
mitofusins at distinct steps in the fusion process. (A) Structural and schematic model
of human Mfn1. Human Mfn1 was modeled on the bacterial homolog BDLP using
i-tasser (C-score −0.80) [157,199]. The N-terminal heptad repeat domain HR1 is
depicted in green, the C-terminal HR2 is depicted in turquoise, the GTPase domain in
blue and the transmembrane domains in black. (B) Model of mitochondrial OM fusion.
Mitofusins are integrated into the OM by two transmembrane domains exposing N-
and C-terminus to the cytosol. Upon GTP binding mitofusins dimerize in one mem-
brane, i.e. in cis, which in yeast depends on Ugo1. Mitochondrial tethering of opposing
organelles occurs by mitofusin trans interactions, presumably GTP hydrolysis-
independent. Two alternative mitofusin trans interactions are shown, both speculative.
In the model on the left side, mitofusins interact in trans via their GTPase domains, in
accordance with the interactions observed between the GTPase domains in the open
conformation of BDLP [158]. In an alternative model, depicted on the right side,
mitofusin dimers interact in trans involving anti-parallel associations between the
C-terminal helices, as previously proposed [128]. Subsequently, GTP hydrolysis enables
mitofusin ubiquitylation and turnover, possibly allowing membrane approximation.
Finally, MitoPLD in mammals and Ugo1 in yeast facilitate the last membrane merging
step in OM fusion, resulting in fused mitochondrial OMs. The arrows indicate the
conformational changes at the hinge regions based on the different conformations
observed with BDLP [158].
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overexpression of mitochondrial bound C-terminal coiled coil caused
mitochondrial aggregation or induced mitochondrial clustering [37].
However, it is currently not clear how to reconcile such an antiparal-
lel association with the structural data from EHD2 or BDLP, where in-
teractions between the G domains appear to be a constant feature
[157,161,162].
6.1.2. GTPase properties of mitofusins—binding and hydrolysis of GTP are
required at distinct steps of OM fusion
In both yeast and mammals, nucleotide binding enables
mitofusins to adopt a dimeric conformation in cis, whereas GTP hy-
drolysis occurs only after trans associations between two mitochon-
dria [47,48,124]. In analogy to other DRPs, GTP hydrolysis could
trigger a conformational change on the GTP bound stretched arrange-
ment observed for BDLP, but maintaining G domain associations. This
would favor membrane approximation, in agreement with the short
distances observed between two adjacent mitochondria in mitoPLD
mutants [126].
OM fusion occurs at lower rates of GTP, but requires GTP binding
and hydrolysis. In EHD2, the slow rate of nucleotide hydrolysis is cor-
related to extensive tubule formation [162]. Therefore, slow hydroly-
sis rates could favor mitofusin self-assembly over disassembly,
promoting membrane tubulation and mediating lipid bilayer destabi-
lization, followed by fusion. Alternatively, in Atlastins it was shown
that GTP hydrolysis occurs after ER membrane fusion, making it pos-
sible that mitochondria also have such a post-fusion GTP hydrolysis
role that would favor mitofusin disassembly and recycling [163].
6.1.3. Ubiquitylation of Fzo1 as a positive drive for mitochondrial fusion
It was shown that the SCFMdm30 E3 ligase controls ubiquitylation
of the yeast mitofusin [124], at late stages during the fusion cycle,
given that GTP hydrolysis is required for this post-translational mod-
iﬁcation [47,123,124]. Compatible with the aforementioned GTP
hydrolysis-induced conformational change of mitofusins, the interac-
tion of Mdm30 with the GTPase domain of Fzo1 was inhibited in
full-length GTPase mutants [124]. In addition, this interaction was re-
stored after deletion of the C-terminal domain of Fzo1, compatible
with a closed and static conformation in GTP binding mutants. As
Mdm30 also mediates Fzo1 turnover [111], several laboratories pro-
posed that ubiquitylation and clearance of mitofusins would, at a
late stage, facilitate close membrane approximation, necessary for
completion of fusion [47,123,124]. Interestingly, two arguments sug-
gest that Mdm30 could regulate Fzo1 turnover in a non-classical
manner: overexpression of Mdm30 lacking the F-box motif partially
complemented the turnover of Fzo1 [112] and completely rescued
the morphologic defects of Δmdm30 cells [121]. Consistent with this
role for yeast mitofusin turnover in OM fusion, the BDLP homolog
from Bacillus subtilis, which can tether apposing membranes, led to
membrane fusion upon protease addition [164].
6.1.4. Mfn1 and Mfn2—redundant yet different
The existence of two mitofusins in mammalian cells, Mfn1 and
Mfn2, raises the question of their individual roles in OM fusion. Only si-
multaneous deletion of Mfn1 and Mfn2 completely inhibits mitochon-
drial OM fusion, clearly demonstrating their redundant nature.
Consistently, overexpression of Mfn2 in Mfn1 deﬁcient cells was sufﬁ-
cient to rescue mitochondrial morphology and vice versa, although to a
lower extent [4]. In fact, Mfn1 and Mfn2 form both homotypic and het-
erotypic complexes [4,40]. In addition, the C-terminal coiled coil of
Mfn1 physically interacts with both Mfn1 and Mfn2 [128].
Although there are redundancies, both Mfn1 and Mfn2 are re-
quired for optimal OM fusion levels in vitro, suggesting that each
may have speciﬁc functions [25]. They do show exclusive roles and
KO of Mfn1 or Mfn2 results in different mitochondrial morphologies
[4]. Absence of Mfn1 in mammals, and also Fzo1 mutants in yeast,presents numerous small mitochondria scattered throughout the cy-
toplasm [4,26,27,40]. Loss of Mfn2 in mammals also leads to
mitochondrial fragmentation, however the fragments are larger, het-
erogeneous in size, and sometimes accumulate perinuclearly [4,40].
Depletion of both Mfn1 and Mfn2 gives rise to a mitochondrial mor-
phology resembling depletion of Mfn1 alone [40]. Moreover, after
Mfn1 depletion intermixing of two non-fused mitochondrial popu-
lations is unaffected [40]. In contrast, no intermixing was detected
following Mfn2 depletion, suggesting that Mfn2 is involved in the
cellular positioning of mitochondria [40].
Attesting for the differences between both mitofusins is the fact
that mutations in Mfn2 but not in Mfn1 cause the Charcot–Marie–
Tooth type 2A (CMT2A) neuropathy. Moreover, mitochondrial fusion
or transport defects in CMT2Amutant cell lines can be complemented
by overexpressing Mfn1 but not Mfn2 [165,166]. In fact, Mfn1 and
Mfn2 are expressed differently in different tissues, being Mfn1 ex-
pression higher in more tissues than Mfn2 [39,40]. However, Mfn2
is the prevalent species in heart, skeletal muscle and brain [39,40].
This provides a possible explanation for the neurodegenerative disor-
ders and cardiopathies speciﬁcally associated with Mfn2. Obesity or
diabetes lead to a reduced expression of Mfn2 [42,167,168] and
Mfn2 has been related to several cellular functions such as oxidative
metabolism, cell cycle, cell death and mitochondrial axonal transport
[169]. Interestingly, Mfn2 binds to Miro, an adaptor to the kinesin
motor proteins and to microtubules [166]. Consistently, Mfn2 deple-
tion inhibits axonal transport of mitochondria or proper mitochondri-
al positioning within neurons [166,170,171]. This could account for
the axonal survival dependence onmitochondrial fusion, contributing
to the neurological phenotypes associated with Mfn2 mutations.
Several other differences have been observed between Mfn1 and
Mfn2, further suggesting that each Mfn protein has specialized func-
tions, and this both within and outside OM fusion. For example,
Mfn2 was suggested to play a role in tethering between mitochondria
and the ER [172] and OPA1 was shown to require Mfn1 but not Mfn2
to induce mitochondrial tubulation [90]. Moreover, in vitro analyses
showed that Mfn1 mediates mitochondrial tethering more efﬁciently
than Mfn2 [48]. Consistently, the oligomerization changes observed
for Fzo1 and Mfn1 upon tethering were not obvious for the Mfn2 pro-
tein [47,48]. However, cells expressing only Mfn1 fused in vitro to
cells expressing only Mfn2, suggesting that trans associations be-
tween Mfn2 and Mfn1 are sufﬁcient to drive OM fusion [25]. The sit-
uation was different in cellular culture, because Mfn1 depleted cells
did not fuse with Mfn2 depleted cells [46]. Finally, Mfn1 andMfn2 ap-
pear to have different GTP binding and hydrolysis properties [48].
Mfn2 resembles more small regulatory signaling GTPases like Ras,
with high GTP binding and low GTP hydrolysis, whereas Mfn1 and
Fzo1 resemble the mechanical DRPs. Along this line, a signaling func-
tion has been proposed for human Mfn2, because a mutant form of
Mfn2 constitutively GTP-bound was functional and capable of accel-
erating fusion [173]. However, it would be interesting to test a similar
constitutively GTP-bound mutation in Mfn1. Based on these observa-
tions we may speculate that Mfn1 would be primarily involved in mi-
tochondrial tethering, more similar to the classical DRPs, whereas
Mfn2 would mainly assume a regulatory role, closer to the Ras-like
regulatory GTPases. However, how these two proteins cooperate to
co-ordinate mitochondrial fusion is not yet clear. Consistent with
this concept is the proposed positive regulatory role of Bax in mito-
chondrial fusion exclusively via Mfn2. The idea that Mfn2 could act
after mitochondrial tethering is supported by the clustering but fu-
sion impairment observed after depletion or KO of Mfn2 [4,40].
6.2. IM fusion model
It is now clear that IM fusion requires an initial and conserved step
involving partial cleavage of the long to short isoform(s) of Mgm1/
OPA1 [77,78]. In addition, and in analogy to mitofusins, these DRPs
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direct contacts once OM fusion has occurred. Although it was shown
that both homo and hetero-oligomers of long and short forms exist
[91,92,156], precisions on the oligomeric order and composition
that promotes fusion are not yet known. Interestingly, proteolytic
processing stimulates GTPase activity providing a rational basis for
the requirement of a combination of both short and long isoforms
[92]. It is possible that the long forms contribute in membrane tether-
ing, whereas the short forms contribute with GTPase activity [92]. As
expected, both phospholipid interaction and oligomerization are re-
quired for stimulated GTPase activity [92,174]. These ﬁndings, further
detailed below, applied to modeling of splice variant 7 of OPA1 to the
structure of human dynamin [159,160] allow one to propose the
model depicted in Fig. 3.
6.2.1. Partial proteolytic processing of Mgm1/OPA1 is required for IM
fusion
The ﬁrst step in allowing IM fusion is probably the constitutive par-
tial cleavage of the responsible DRPs to allow the equimolar combina-
tion of both short and long isoforms, as referred above. Clearly, both
isoforms have different properties in terms of membrane association
and GTPase activity, and therefore should play distinct roles in IM fu-
sion, as discussed below. In addition, the submitochondrial distributionprocessing
IM fusion
A
B
l-OPA1 s-l-OPA1/Mgm1
YME1L/Pcp1
Fig. 3. IM fusion model, requiring OPA1/Mgm1 activation, oligomerization and GTP hydrolys
(splice variant 7) was modeled on human dynamin using i-tasser (C-score−1.98) [159,160
ange. (B) Model for mitochondrial IM fusion. L-OPA1 is anchored to the IM by an N-termin
partially cleaved by YME1L/Pcp1, generating an equilibrium between the two isoforms, whi
Mgm1. GTP hydrolysis probably induces a conformational change possibly triggering conver
tional change at the hinge region upon GTP hydrolysis based on dynamin [159,160].of the long and short isoforms ofMgm1 between inner boundarymem-
brane and cristae was markedly different [91]. Enrichment of the long
isoform in cristae, added to the fact that these forms are devoid of
GTPase activity [91,92], is consistent with the proposed role of the
homotypic interactions in maintaining cristae structure [22,75].
6.2.2. Oligomerization of Mgm1/OPA1 in cis and in trans
An indication that IM tethering precedes IM fusion came from the
observation that some mutant alleles of Mgm1, blocked for IM fusion
in vitro, could still clearly tether IM from isolated mitochondria [22].
Importantly, other mutant alleles of Mgm1 had lost the capacity for
IM tethering, indicating a crucial role for the IM DRPs in IM tethering.
In addition, in vitro studies showed intra-allelic complementation of
inactive Mgm1 isoforms expressed in separate populations of mito-
chondria, suggesting that self‐oligomerization in trans drives IM fu-
sion. Moreover, physical interactions between Mgm1 subunits have
been observed, including evidence for both homotypic and hetero-
typic associations of the different isoforms, i.e. long with long, short
with short and long with short [91,92,156]. Therefore, it seems that
IM fusion relies on direct trans interactions between the DRPs of
each fusion partner. These physical interactions between short and
long isoforms in cis and in trans indicate that together they form a
functional dimer in cis, which constitutes the building block fordimerization
tethering
GTP hydrolysis
OPA1
is to achieve fusion. (A) Structural and schematic model of human OPA1. Human OPA1
,199]. The GTPase domain is represented in purple, the helical domains are red and or-
al transmembrane domain, the rest of the protein resides in the IMS. L-OPA1/Mgm1 is
ch dimerize on one membrane. IM tethering involves trans interactions between OPA1/
gence of the opposing membranes before IM fusion. The arrow indicates the conforma-
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sesses one interface to form dimers and a second dimer–dimer inter-
face for the assembly of the higher order structures. In analogy to the
ﬁssion dynamins, it is formally possible that OPA1/Mgm1 promotes
highly curved and fusogenic ends, by cis associations to higher order
complexes, promoting membrane budding or tubulation. However,
tubulation was not yet observed and instead ordered lattices were
obtained [92,174]. Although the precise nature and order of the asso-
ciation into a complex of Mgm1/OPA1 have not been reported, it was
proposed that stacked trimers of s-Mgm1 on apposing membranes
would facilitate fusion [174].
6.2.3. GTPase activity requires processing of the IM DRP
It was shown that puriﬁed short forms of Mgm1 possess GTPase
activity, self-assemble into low-order oligomers and bind to negative-
ly charged phospholipids [156]. Moreover, binding to lipids by the
short isoform is required for proper membrane fusion [174]. Consis-
tently, after puriﬁcation and reconstitution in liposomes mimicking
the IM composition, short Mgm1 isoforms acquire GTPase activity in
a cardiolipin-dependent manner [92]. Moreover, GTP binding or hy-
drolysis seems to lead to conformational changes on short Mgm1, in-
dicated by different arrangements on the liposomes in the presence
or absence of GTP. Similarly, in the presence of liposomes mimicking
the IM composition, l-Mgm1 integrated in the membranes apparently
with the correct topology. However, in contrast to s-Mgm1, l-Mgm1
failed in acquiring GTPase activity, possibly because of the sterical
hindrance on GTP hydrolysis by the close proximity of the GTPase
motif to the membrane. 3D reconstruction of puriﬁed s-Mgm1 in the
presence of CL revealed the formation of the dimeric building blocks.
Just like in the OM, IM fusion is abolished in GTPase mutants of
Mgm1/OPA1 [89]. This phenotype allowed one to prove that GTPase- stress + stress
Mitofusin ubi. and turnover
OPA1
complete processing
Mitofusin constitutive ubi.
OPA1/Mgm1 
partial processing
OMA1
OPA1
complete
processing
Parkin
mitofusin
ubiquitylation +
degradation
fusion fragmentation
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Fig. 4. Stress induced fragmentation of mitochondrial fusion. (A) Opposing conse-
quences of mitofusin ubiquitylation and OPA1/Mgm1 processing on mitochondrial
morphology. Ubiquitylation of mitofusins and partial processing of OPA1/Mgm1 are
constitutively required for mitochondrial fusion (− stress). In contrast, cellular stress
(+ stress) results in mitochondrial fragmentation, which also involves ubiquitylation
of mitofusins and processing of OPA1. (B) OM and IM inhibition of mitochondrial fu-
sion by Parkin and OMA1, respectively. Upon stress Parkin ubiquitylates mitofusins
(upper part), thereby mediating their proteasomal degradation and OMA1 completely
processes OPA1 isoforms (lower part). This results in inhibition of mitochondrial fusion
and leads to a fragmented morphology due to ongoing ﬁssion.activity is only required in the short isoforms of the DRP [91,92].
However, maximal GTPase activity requires the additional presence
of long isoforms [92]. Therefore, association of the long isoforms
with the short isoforms appears to activate the GTPase domain of
the short isoforms.
7. Inhibition of mitochondrial fusion by inactivation of the key
fusion mediators
In contrast to the proteolytic processes discussed above, i.e. consti-
tutive proteolysis of mitofusins or the partial processing of Mgm1/
OPA1, which are required for mitochondrial fusion, anti-fusion proteol-
ysis leading to mitochondrial fragmentation also occurs. In fact, a con-
nection between mitochondrial morphology and the energetic or
metabolic status of the cell has long been observed [168]. For example,
dissipation of membrane potential leads to fragmentation of mitochon-
drial tubules [153]. This mechanism plays a quality control and protec-
tive role, where non-functional mitochondria that lose membrane
potential are rendered fusion incompetent and fragment by ongoing
ﬁssion. Therefore, these damaged mitochondria cannot mix to and in-
jure the healthy population and become substrates for the autophagic
pathway [132]. Also the proliferative status impinges on mitochondrial
morphology: in most quiescent cells mitochondria fragment and mito-
chondrial tubules are only restored after growth resumption. This con-
stitutes an essential prerequisite to entry into S phase [175].
Interestingly, in both cases, i.e. mitochondrial dysfunction and transi-
tion to quiescence, it was shown that fragmentation is accompanied
by inactivation of the two key mediators of mitochondrial fusion.
Upon entry into quiescence, it was recently shown that the APC/
CCDH1 E3 ligase triggers ubiquitylation of Mfn1 and OPA1,
recognized as a sign for their proteasomal degradation [176]. This
APC-dependent mechanism could be conserved, as in yeast it was
also shown that mitochondrial fragmentation induced by cellular
growth arrest is accompanied by proteasomal degradation of Fzo1
[177]. Finally, mitochondrial dysfunction leads to ubiquitylation and
turnover of mitofusins and also triggers OPA1 inactivation by elimina-
tion of its long isoforms, as further detailed below (Fig. 4).
7.1. OM fusion inactivation—ubiquitylation of mitofusins as a mark for
destruction
Post-translational modiﬁcations modulate a vast number of cellular
events, one example being ubiquitylation of a protein as a signaling
mark for its destruction. It is clear that ubiquitylation plays a central
and conserved role in mitochondrial dynamics regulation. As stated
above, two opposite outcomes arise from ubiquitylation of mitofusins:
decreased or increased OM fusion, i.e. anti- or pro-fusion. Pro-fusion
ubiquitylation of the yeast mitofusin, which is associated with
the fusion cycle, depends on active GTP binding and hydrolysis
[47,124]. However, the GTPase dependence for mitofusin anti-fusion
ubiquitylation and destruction after membrane depolarization has not
been investigated so far. Whereas the pro-fusion role is played by the
SCFMdm30 in yeast [112], other ubiquitin ligases like the above men-
tioned APC/CCdh1 [176], the recently identiﬁed Huwe1 [178], and
Parkin, mediate the anti-fusion ubiquitylation of mitofusins, in both
ﬂies and mammalian cells [14,179–184]. Huwe1 was shown to be
recruited to the OM upon several apoptotic stimuli, resulting in mito-
chondrial fragmentation. Interestingly, this implied phosphorylation
of Mfn2 by JNK and subsequent ubiquitylation and proteasomal degra-
dation of Mfn2 [178].
Upon dissipation of the membrane potential by CCCP addition,
Parkin accumulates at the OM surface of mitochondria, which results
in elimination of dysfunctional mitochondria [185–187]. However, it is
still unknown if more subtle mitochondrial dysfunctions, more prone
to occur naturally, such as in the context of mitochondrial disease, are
sufﬁcient to accumulate Parkin and trigger the activation of mitophagy.
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depolarized mitochondria. Interestingly, upon mitochondrial depolari-
zation Parkin binds to Miro/Milton, and leads to its proteasomal depen-
dent turnover [188]. This results in detachment of kinesin from
mitochondria, thereby blocking organelle motility, which may segregate
damaged mitochondria to allow their efﬁcient clearance.
In addition to mitofusins, several other substrates ubiquitylated by
Parkin have been identiﬁed, which triggers their turnover by the
proteasome [189,190]. Formation of K48-linked ubiquitin chains and
simultaneous recruitment of the AAA-type ATPase p97/Cdc48 to the
surface of mitochondria have been observed and were proposed to
mediate extraction of the Parkin substrates before their turnover
[191,192]. Mechanistically, little is known on the relevance of this
turnover of OM proteins for PD. Moreover, it will be interesting to an-
alyze the role of another Parkin substrate, PARIS, which mediates the
loss of dopamine neurons, the hallmark of PD [193].
7.2. IM fusion inactivation—impairment of the balance between long and
short OPA1/Mgm1
In addition to the constitutive pro-fusion cleavage of OPA1 at site
S2, under stress conditions an additional cleavage event of the long
OPA1 isoforms at site S1 occurs in mammalian cells [78,83,85,194].
As stated above, partial cleavage of OPA1 at S2 produces a combina-
tion of long and short OPA1 isoforms, required for mitochondrial fu-
sion [78]. In contrast, complete conversion of long to short OPA1
isoforms at site S1 hampers mitochondrial fusion. Several conditions
result in this stress-induced cleavage at site S1, including low ATP
levels, dissipation of the membrane potential, cold- or heat-stress, in-
duction of apoptosis or depletion of crucial mitochondrial proteins
like Prohibitins or the m-AAA protease [78,83,85–88,194–198]. The
protease performing this inducible cleavage is the ATP-independent
zinc metalloprotease OMA1 [86–88]. However, it is not yet clear
how stress activates OPA1 cleavage, which is also occurring in isolat-
ed mitochondria after dissipation of the membrane potential [25].
OMA1 KO mice present several metabolic dysfunctions, suggesting
that this protease could be a general sensor of metabolic stress [88].
In addition, a role for PARL in OPA1 cleavage has been proposed
[76,198]. However, OPA1 processing was unaffected in both mice
and ﬂy mutated or completely depleted of the PARL proteins, along
with the absence of mitochondrial fragmentation [85,98].
8. Concluding remarks
Mitochondrial membrane fusion has progressed from the genetic
identiﬁcation and biochemical characterization of the relevant pro-
teins, i.e. determination of their associations and topologies, to the
current era of mechanistic studies. Clearly, a major challenge for the
future is to study each of the proteins identiﬁed using reconstituted
systems like proteoliposomes. This will not only enhance the under-
standing of the role of each component so far identiﬁed but also
allow one to further stage the molecular mechanisms required for fu-
sion of each of the mitochondrial membranes. Moreover, it is getting
increasingly clear that mitochondria function as signaling platforms
and future experiments, certainly facilitated by the recently devel-
oped automated assay for quantifying mitochondrial fusion, will
allow one to shed light on the molecular implications of mitochondri-
al fusion in disease.
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